Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen Inc. (NASDAQ:AMGN) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. Amgen Inc. (NASDAQ:AMGN) is on ...

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 ...

(NASDAQ:AMGN) share price is up 22% in the last three years, that falls short of the market return. Disappointingly, the ...

Amgen's expanding rare disease and biosimilar portfolios, coupled with growth potential and dividend history make AMGN stock ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

On Nov. 26, 2019, ChemoCentryx issued a press release announcing that the Advocate trial met both of its primary endpoints, saying Tavneos showed noninferiority of disease remission at 26 weeks and ...

On July 16, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement ...

Biotech pioneer Amgen (AMGN-0.07%) has several key elements of a good dividend stock. The company has raised its payout for 12 straight years, free cash flows have remained steady at a little over ...

The Federal Trade Commission announced Friday it had reached a settlement with Amgen Inc. over the biopharmaceutical firm’s $27.8 billion acquisition of Horizon Therapeutics, after the agency ...

Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.